시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 차세대 체외진단약(IVD) 시장 보고서(2025년)
Next-Generation In Vitro Diagnostics (IVD) Global Market Report 2025
상품코드 : 1810975
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,457,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,334,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,211,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

차세대 체외진단약(IVD) 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년 연평균 성장률(CAGR)은 9.9%로, 1,720억 2,000만 달러로 성장합니다. 예측 기간의 성장은 맞춤형 의료의 발전, 의료비 지출 증가, 연구개발 활동 활성화, 감염성 질환 유병률 증가, 만성질환 환자 급증에 기인합니다. 예측 기간 중 주요 동향으로는 기술 혁신, 진단에 인공지능 및 머신러닝 도입, 첨단 진단 기술 발전, 맞춤형 의료, 신규 바이오마커 발견 등을 꼽을 수 있습니다.

맞춤형 의료에 대한 수요 증가는 향후 차세대 체외진단제(IVD) 시장의 성장을 촉진할 것으로 예측됩니다. 맞춤형 의료는 개인의 유전자 프로파일, 환경, 라이프스타일에 따라 질병 예방과 치료를 조정하는 헬스케어 접근법입니다. 맞춤형 의료의 성장은 유전체 데이터의 가용성이 증가함에 따라 의료 서비스 프로바이더가 개인의 유전적 구성에 따라 표적 치료법을 개발할 수 있게 됨에 따라 더욱 효과적인 치료가 가능해졌습니다. 차세대 체외진단(IVD)은 환자 개개인에 맞는 치료 및 예방 전략을 촉진하는 정확한 분자 및 유전적 인사이트를 제공함으로써 맞춤형 의료를 지원합니다. 예를 들어 2024년 2월 미국 기반 병원 및 헬스케어 단체인 개인화된 의학 연합(Personalized Medicine Coalition)은 FDA가 2023년 희귀질환 환자를 위한 16개의 새로운 개인화된 치료법을 승인했다고 보고했습니다. 따라서 맞춤형 의료에 대한 수요 증가는 차세대 체외진단(IVD) 시장 확대를 견인하고 있습니다.

차세대 체외진단(IVD) 시장의 주요 업체들은 기술 프로바이더, 연구기관, 의료기관과 전략적 파트너십을 맺고 혁신을 가속화하고, 진단 정확도를 향상시키며, 개인, 기업, 정부를 위한 첨단 검사 솔루션에 대한 접근성을 확대하기 위해 협력하고 있습니다. 전략적 파트너십은 기업이 서로의 강점과 자원을 활용하여 공동의 이익과 성공을 달성하는 것입니다. 예를 들어 2024년 10월 영국의 생명공학 기업 유어진 헬스(Eugene Health)는 콜롬비아의 인간 유전자 진단 기업 제네틱스(Genetics)와 제휴하여 콜롬비아 최초의 현지 비침습적 산전검사(NIPT) 서비스를 도입했습니다. 이는 이 지역 산전 진단의 중요한 진전이며, 임산부 부모에게 보다 신속하고 신뢰할 수 있으며 비용 효율적인 고급 유전자 검사에 대한 접근성을 제공하는 것입니다. 이 서비스는 CE 마크를 획득한 종합 체외진단(IVD) 솔루션인 Yourgene Health의 IONA Nx NIPT 워크플로우를 채택하고 있습니다. 이 워크플로는 유연성과 확장성이 뛰어나고 다양한 샘플 양을 처리할 수 있으므로 Genetix는 콜롬비아 전역에서 품질이 보장된 산전 검사 서비스를 제공할 수 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Next-generation in vitro diagnostics (IVD) refers to advanced diagnostic tools and technologies that examine biological samples-such as blood, saliva, or tissue-outside the body to identify diseases, conditions, or infections with enhanced accuracy, speed, and personalization. These technologies often incorporate innovations like genomics, artificial intelligence, digital health platforms, and high-throughput sequencing. The main goal of next-generation IVD is to facilitate earlier, more precise, and patient-tailored diagnosis and monitoring of diseases, including cancer, infectious diseases, and genetic disorders.

The primary product categories in next-generation in vitro diagnostics (IVD) include consumables, instruments, software, and others. Core laboratory diagnostics involve centralized testing services that process a wide variety of biological samples using automated, high-throughput instruments and assays. This encompasses types such as core laboratory diagnostics, point-of-care testing, and molecular diagnostics. These tools are applied across various fields, including oncology, infectious diseases, diabetes, cardiology, and other diagnostic areas, serving a diverse range of end users like hospitals and clinics, diagnostic laboratories, academic and research institutions, and other healthcare providers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The next-generation in vitro diagnostics (IVD) market research report is one of a series of new reports from The Business Research Company that provides next-generation in vitro diagnostics (IVD) market statistics, including next-generation in vitro diagnostics (IVD) industry global market size, regional shares, competitors with a next-generation in vitro diagnostics (IVD) market share, detailed next-generation in vitro diagnostics (IVD) market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation in vitro diagnostics (IVD) industry. This next-generation in vitro diagnostics (IVD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next-generation in vitro diagnostics (IVD) market size has grown rapidly in recent years. It will grow from $106.97 billion in 2024 to $117.97 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the growing geriatric population, increased government funding, escalating investments in genomic research, expansion in clinical trials, and greater consumer health awareness.

The next-generation in vitro diagnostics (IVD) market size is expected to see strong growth in the next few years. It will grow to $172.02 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be credited to the expanding advancement of personalized medicine, rising healthcare expenditures, increasing research and development activities, growing incidence of infectious diseases, and a surge in chronic disease cases. Key trends during the forecast period include technological innovations, the incorporation of artificial intelligence and machine learning in diagnostics, progress in advanced diagnostic technologies, personalized medicine, and the discovery of novel biomarkers.

The rising demand for personalized medicine is expected to drive the growth of the next-generation in vitro diagnostics (IVD) market moving forward. Precision medicine is a healthcare approach that tailors disease prevention and treatment based on an individual's genetic profile, environment, and lifestyle. The growth of personalized medicine is fueled by the increasing availability of genomic data, enabling healthcare providers to develop targeted treatments based on a person's unique genetic makeup, resulting in more effective care. Next-generation in vitro diagnostics (IVD) supports personalized medicine by delivering precise molecular and genetic insights that facilitate customized treatment and prevention strategies for individual patients. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022. Therefore, the growing demand for personalized medicine is driving the expansion of the next-generation in vitro diagnostics (IVD) market.

Key players in the next-generation in vitro diagnostics (IVD) market are adopting strategic partnerships by collaborating with technology providers, research institutions, and healthcare organizations to accelerate innovation, improve diagnostic accuracy, and broaden access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve shared benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology company, partnered with Genetix, a Colombia-based human genetic diagnosis company, to introduce Colombia's first local non-invasive prenatal testing (NIPT) service. This initiative marks a significant advancement in prenatal care within the region, providing expectant parents with faster, more reliable, and cost-effective access to advanced genetic screening. The service employs Yourgene Health's IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is highly flexible and scalable, accommodating varying sample volumes, and enables Genetix to offer a quality-assured prenatal screening service throughout Colombia.

In February 2023, SD Biosensor Inc., a South Korea-based in-vitro diagnostics company, along with SJL Partners LLC, a South Korea-based investment firm, acquired Meridian Bioscience Inc. for $1.53 billion. Through this acquisition, SD Biosensor aims to leverage Meridian's expertise in diagnostic products and raw materials used in immunological and molecular tests across various applications. Meridian Bioscience Inc. is a US-based diagnostic company specializing in in vitro diagnostic enzymes.

Major players in the next-generation in vitro diagnostics (IVD) market are F Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Quest Diagnostics Incorporated, Grifols SA, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Revvity Inc., Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc., Guardant Health Inc., Pacific Biosciences of California Inc., Transasia Bio-Medicals Ltd., Athena Dx, and J Mitra and Co Pvt Ltd.

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in next-generation in vitro diagnostics (IVD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the next-generation in vitro diagnostics (IVD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next-generation in vitro diagnostics (IVD) market consists of revenues earned by entities providing services such as genomic testing services, molecular diagnostics services, and companion diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation in vitro diagnostics (IVD) market also includes sales of molecular diagnostics kits, proteomics-based diagnostic kits, and NGS sample preparation kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next-Generation In Vitro Diagnostics (IVD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next-generation in vitro diagnostics (ivd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for next-generation in vitro diagnostics (ivd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next-generation in vitro diagnostics (ivd) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Next-Generation In Vitro Diagnostics (IVD) Market Characteristics

3. Next-Generation In Vitro Diagnostics (IVD) Market Trends And Strategies

4. Next-Generation In Vitro Diagnostics (IVD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Next-Generation In Vitro Diagnostics (IVD) Growth Analysis And Strategic Analysis Framework

6. Next-Generation In Vitro Diagnostics (IVD) Market Segmentation

7. Next-Generation In Vitro Diagnostics (IVD) Market Regional And Country Analysis

8. Asia-Pacific Next-Generation In Vitro Diagnostics (IVD) Market

9. China Next-Generation In Vitro Diagnostics (IVD) Market

10. India Next-Generation In Vitro Diagnostics (IVD) Market

11. Japan Next-Generation In Vitro Diagnostics (IVD) Market

12. Australia Next-Generation In Vitro Diagnostics (IVD) Market

13. Indonesia Next-Generation In Vitro Diagnostics (IVD) Market

14. South Korea Next-Generation In Vitro Diagnostics (IVD) Market

15. Western Europe Next-Generation In Vitro Diagnostics (IVD) Market

16. UK Next-Generation In Vitro Diagnostics (IVD) Market

17. Germany Next-Generation In Vitro Diagnostics (IVD) Market

18. France Next-Generation In Vitro Diagnostics (IVD) Market

19. Italy Next-Generation In Vitro Diagnostics (IVD) Market

20. Spain Next-Generation In Vitro Diagnostics (IVD) Market

21. Eastern Europe Next-Generation In Vitro Diagnostics (IVD) Market

22. Russia Next-Generation In Vitro Diagnostics (IVD) Market

23. North America Next-Generation In Vitro Diagnostics (IVD) Market

24. USA Next-Generation In Vitro Diagnostics (IVD) Market

25. Canada Next-Generation In Vitro Diagnostics (IVD) Market

26. South America Next-Generation In Vitro Diagnostics (IVD) Market

27. Brazil Next-Generation In Vitro Diagnostics (IVD) Market

28. Middle East Next-Generation In Vitro Diagnostics (IVD) Market

29. Africa Next-Generation In Vitro Diagnostics (IVD) Market

30. Next-Generation In Vitro Diagnostics (IVD) Market Competitive Landscape And Company Profiles

31. Next-Generation In Vitro Diagnostics (IVD) Market Other Major And Innovative Companies

32. Global Next-Generation In Vitro Diagnostics (IVD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next-Generation In Vitro Diagnostics (IVD) Market

34. Recent Developments In The Next-Generation In Vitro Diagnostics (IVD) Market

35. Next-Generation In Vitro Diagnostics (IVD) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기